JAC Advance Access originally published online on December 1, 2006
Journal of Antimicrobial Chemotherapy 2007 59(1):159-160; doi:10.1093/jac/dkl462
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Correspondence |
Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammationauthor's response
Department of Infectious Diseases and Immunity, Hammersmith Hospital, Imperial College London Du Cane Road, London W12 0NN, UK
*Correponding author. Tel: +44-208-383-3135; Fax: +44-208-383-3394; E-mail: s.sriskandan@imperial.ac.uk
Keywords: bacterial infections , models , septic shock , Streptococcus pyogenes , immunology , immunomodulators
| The first 10% of the full text of this article appears below. |
Sir,
The failure of Rajagopalan et al.1 to demonstrate any effect of intravenous immunoglobulin (IVIg) in vitro is perplexing, as several investigators have demonstrated the inhibitory properties of IVIg on superantigen-induced T cell mitogenesis and blast formation in vitro.26 Although variation in IVIg source may partly explain their results, the
Transparency declarations